Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at
Wall
Aptar's Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval [Yahoo! Finance]
Milestone Pharmaceuticals (NASDAQ:MIST) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray [Yahoo! Finance]